At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,060 enrolled
Drug / intervention
TD-4208 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, 52-week, Randomized, Active-Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease
In Brief
A Phase 3 clinical trial evaluating TD-4208 and Tiotropium for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 1,060 participants across 1 site.
Detailed Summary
The purpose of this study is to measure the safety and tolerability of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to tiotropium.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsTheravance Biopharma
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartSep 2015
Primary CompletionJun 2017
TodayJul 2026
First PostedAug 7, 2015
Enrollment StartSep 1, 2015
Primary CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 10.9 years ago
Interventions
TD-4208drug
Subjects receiving TD-4208 are blinded to one of two doses of 4208.
Tiotropiumdrug
There is not a placebo, there is an active comparator (Tiotropium) arm.